ABL Bio Inc - Asset Resilience Ratio
ABL Bio Inc (298380) has an Asset Resilience Ratio of 1.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does ABL Bio Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how ABL Bio Inc's Asset Resilience Ratio has changed over time. See ABL Bio Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ABL Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 298380 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.96 Billion | 1.05% |
| Total Liquid Assets | ₩2.96 Billion | 1.05% |
Asset Resilience Insights
- Limited Liquidity: ABL Bio Inc maintains only 1.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ABL Bio Inc Industry Peers by Asset Resilience Ratio
Compare ABL Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ABL Bio Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for ABL Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.05% | ₩2.96 Billion ≈ $2.01 Million |
₩280.93 Billion ≈ $190.39 Million |
-59.58pp |
| 2024-12-31 | 60.64% | ₩140.66 Billion ≈ $95.32 Million |
₩231.98 Billion ≈ $157.21 Million |
+16.21pp |
| 2023-12-31 | 44.43% | ₩71.15 Billion ≈ $48.22 Million |
₩160.14 Billion ≈ $108.53 Million |
+2.14pp |
| 2022-12-31 | 42.29% | ₩78.32 Billion ≈ $53.07 Million |
₩185.18 Billion ≈ $125.49 Million |
-24.39pp |
| 2021-12-31 | 66.68% | ₩43.65 Billion ≈ $29.58 Million |
₩65.45 Billion ≈ $44.36 Million |
-3.78pp |
| 2020-12-31 | 70.47% | ₩70.39 Billion ≈ $47.70 Million |
₩99.89 Billion ≈ $67.70 Million |
-22.81pp |
| 2019-12-31 | 93.27% | ₩133.29 Billion ≈ $90.33 Million |
₩142.90 Billion ≈ $96.84 Million |
+10.41pp |
| 2018-12-31 | 82.86% | ₩139.92 Billion ≈ $94.82 Million |
₩168.87 Billion ≈ $114.44 Million |
+37.84pp |
| 2017-12-31 | 45.02% | ₩9.17 Billion ≈ $6.21 Million |
₩20.37 Billion ≈ $13.80 Million |
-25.89pp |
| 2016-12-31 | 70.91% | ₩5.34 Billion ≈ $3.62 Million |
₩7.53 Billion ≈ $5.10 Million |
-- |
About ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more